13.06.2022 • NewsSamsung BiologicsNovartisLonza

Samsung Biologics in $81 Million Deal with Novartis

In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development deal, Samsung said in a regulatory filing.

The Korean biotech, part of the vast Samsung industrial conglomerate, said the agreement represents 6.4% of its 2021 sales of $1.25 billion. It did not reveal details of what the cooperation with Novartis would involve, but analysts said the deal s fits well with the company’s plans to build up a global position in the CDMO sphere.

Samsung Biologics currently collaborates with a number of international drugmakers, and according to Korean press reports, it is swiftly gaining traction against its peers. In two trading days at the end of April, it squeaked by the world’s biggest CDMO, Lonza, in market capitalization, with a currency adjusted converted market cap of 59.43 trillion Korean won to Lonza’s 55.62 trillion won (42.85 Swiss francs).

The Samsung offshoot is already seen as ahead of Lonza in production capacity with current output of 364,000 liters at Plants 1, 2 and 3, compared with the Swiss CDMO’s 303,000 liters. When Plant 4, designed as the world’s largest single plant with a production capacity of 256,000 liters, is completed in 2023, its capacity will rise to 620,000 liters. 

As a major step toward lifting its profile, in February this year Samsung Biologics said it would buy out US biologics giant Biogen to take full control of joint venture Samsung Bioepis for $2.3 billion. Through the buyout, CEO John Rim said the Korean firm aims to develop into a biopharmaceutical firm on three pillars: CDMO, biosimilars and new drug development.

Author: Dede Williams, Freelance Journalist

(c) Samsung Biologics
(c) Samsung Biologics

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

most read

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.